AllianceBernstein
CADX

AllianceBernstein’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

AllianceBernstein’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-116,214
Closed -$1.05M – 3745
2013
Q4 		$1.05M Sell
116,214
-4,900
-4% -$35.4K ﹤0.01% 2126
2013
Q3 		$764K Sell
121,114
-48,199
-28% -$306K ﹤0.01% 2268
2013
Q2 		$1.16M Buy
+169,313
New +$1.18M ﹤0.01% 1986

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AllianceBernstein's CADX Position: Q1 2014 in Review

AllianceBernstein sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 116,214 shares — an estimated $1.05M sold.

AllianceBernstein first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $1.16M in Q2 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • AllianceBernstein reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • AllianceBernstein sold 116,214 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $1.05M.
  • AllianceBernstein first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • AllianceBernstein's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $1.16M in Q2 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on AllianceBernstein's 13F filing for Q1 2014, filed 13 May 2014.